Skip to content

#Paper

19 NovThu
30 OctFri
  1. Europe PMC: new psychedelic research papers55

    Psilocybin with psychological support for anhedonia in treatment-resistant depression: a randomised controlled pilot trial

    A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.

28 OctWed
  1. OPEN Foundation62

    OPEN Foundation reviews study on how psilocybin aligns brain activity with sensory context

    OPEN Foundation summarises a study by Stoliker and colleagues, described as the largest single-site psychedelic neuroimaging study to date, in which 62 healthy adults aged 18 to 55 with no previous meaningful psychedelic experience received a single 19 mg oral dose of psilocybin and underwent fMRI and EEG recordings across rest, guided meditation, music listening and movie viewing.